Kathrine Tuttle, MD
Nephrology · Spokane, WANPI 1740399492
Payments from drug & device makers
Across 998 payments — averaging $1889.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$878K
- Travere Therapeutics, Inc.$286K
- Novo Nordisk AS$180K
- Gilead$178K
- Novo Nordisk$77K
- Boehringer Ingelheim International GmbH$74K
- plus $213K from 26 others
Across 29 payments — averaging $2524.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$67K
- Bayer$4K
- Eli Lilly$2K
What the payments were for
- Consulting fees$258,97862%
- Speaking & faculty fees$51,01012%
- Travel & lodging$105,93425%
- Food & beverage$5,1391%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 44 | $878,087 |
| Travere Therapeutics, Inc. | 129 | $286,301 |
| Novo Nordisk AS | 373 | $179,636 |
| Gilead | 34 | $177,948 |
| Novo Nordisk | 234 | $76,892 |
| Boehringer Ingelheim International GmbH | 53 | $73,782 |
| Boehringer Ingelheim | 15 | $64,977 |
| AstraZeneca | 11 | $30,137 |
| Astrazeneca UK Limited | 12 | $26,892 |
| Lilly USA, LLC | 13 | $16,858 |
| Kyowa Kirin Co., Ltd | 10 | $15,868 |
| Janssen Research & Development, LLC | 3 | $8,150 |
| Bayer | 18 | $7,455 |
| Pfizer | 4 | $7,365 |
| Janssen Scientific Affairs, LLC | 5 | $7,197 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $5,268 |
| Alnylam Pharmaceuticals Inc. | 1 | $4,900 |
| GSK | 2 | $4,245 |
| Astrazeneca AB | 4 | $3,370 |
| Boehringer Ingelheim Singapore Pte. Ltd. | 1 | $2,750 |
| F. Hoffmann-la Roche AG | 1 | $2,620 |
| Merck | 2 | $2,000 |
| Roche Products Limited | 1 | $1,638 |
| Astellas Pharma Inc | 1 | $651 |
| Corcept Therapeutics | 2 | $137 |
| Vifor Pharma, Inc. | 2 | $89 |
| Amgen | 4 | $80 |
| Calliditas Therapeutics US Inc. | 2 | $54 |
| Genentech USA, Inc. | 3 | $49 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,885,452 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $26,948 |
| JardianceEmpagliflozin | 25 | $22,757 |
| FarxigaDapagliflozin Propanediol | 13 | $22,740 |
| OzempicSemaglutide | 18 | $17,520 |
| TrulicityDulaglutide | 15 | $14,143 |
| KerendiaFinerenone | 16 | $13,883 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,382 |
| Torsemide | 16 | $484 |
| Allopurinol | 23 | $380 |
| Losartan Potassium | 25 | $315 |
| Amlodipine Besylate | 23 | $281 |
| Potassium Chloride | 13 | $275 |
| Metoprolol Succinate | 17 | $263 |
| Spironolactone | 33 | $240 |
| Furosemide | 24 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $16,858 | $41,09226 claims |
| Boehringer IngelheimJardiance | $64,977 | $22,75725 claims |
| AstraZenecaFarxiga | $30,137 | $22,74013 claims |
| Novo NordiskOzempic | $76,892 | $17,52018 claims |
| BayerKerendia | $7,455 | $13,88316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 nephrology providers in Washington.
Other nephrology in Spokane
- Matthew RaySpokane$136K
- Saed NemrSpokane$4K
- Krishna MalireddiSpokane$3K
- Vijayakumar ReddySpokane$2K
- Nelson ChowSpokane$2K
- John MusaSpokane$1K
- Sean SanchezSpokane$1K
- Henry MrochSpokane$1K
- Nelio Guzman AguayoSpokane$1K
- Osama AmroSeattle$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.